TURALIO
Mar 03, 2025
Ono’s ROMVIMZA Triumph Sparks Battle with Daiichi Sankyo’s TURALIO in TGCT Space
Ono Pharmaceuticals received FDA approval on 14 February 2025 for vimseltinib, a treatment for tenosynovial giant cell tumor (TGCT), which will be sold under the brand name ROMVIMZA. This approval positions Ono in direct competition with fellow Japanese pharmaceutical company Daiichi Sankyo in the TGCT market. ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
